Delaware
|
001-36323
|
20-4580525
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders
|
(a)
|
The Company’s annual meeting of stockholders was held on June 2, 2015.
|
(b) The stockholders elected all of the Company’s nominees for directors and ratified the appointment of Ernst and Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2015. The tabulation of votes for each proposal is as follows:
|
||
|
1) Election of Directors:
|
For
|
Withhold
|
Broker Non-Votes
|
|||||||
Timothy P. Noyes
|
14,466,568
|
194,940
|
580,094
|
||||||
Garen Bohlin
|
14,587,739
|
73,769
|
580,094
|
||||||
John G. Freund, M.D.
|
14,466,864
|
194,644
|
580,094
|
2) Ratification of Independent Registered Public Accounting Firm:
|
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|||||
15,229,114
|
6,000
|
6,488
|
0
|
Proteon Therapeutics, Inc.
|
||
By:
|
/s/ Timothy P. Noyes
|
|
Name:
|
Timothy P. Noyes
|
|
Title:
|
President & Chief Executive Officer
|